EZZ Shares EZZ Life Science Holdings Limited
ASX · ASXLast in our picks 2026-09-27 — not in the current list; analysis below is from that screen
Listed biotech-adjacent growth name with better liquidity and earnings momentum than peers.
Signal breakdown
- ▸Momentum and earnings growth support a constructive stance.
- ▾Below 50-day MA (-15.54%)
- ▸Volume 1.66× average — accumulation
- ▾Near 52-week low (1.7% of range)
Is EZZ a buy right now?
Trend: EZZ is trading below the 50-day average (-27.38%), RSI 30 — neutral momentum, with a 3-month return of -36.46%.
Valuation & quality: EZZ Life Science Holdings Limited trades on forward P/E 1.3, price-to-book 0.59; fundamentals show net margin -11.5%, return on equity -20.3%, revenue growth -49.5% year on year.
Income: trailing dividend yield 13.11%.
Our screen: BUY (score 2) — Listed biotech-adjacent growth name with better liquidity and earnings momentum than peers.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -44.80% | -17.60% | -10.00% | -41.30% | +29.70% | +20.80% | -32.80% | -20.50% |
Fundamentals
Technical signals
About EZZ Life Science Holdings Limited
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, South-East Asia, and internationally. The company operates through two segments, Brought in Lines and Company Owned Products.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.